Moderna (MRNA) stock price, revenue, and financials

Moderna market cap is $128.9 b, and annual revenue was $803.4 m in FY 2020

$128.9 B

MRNA Mkt cap, 21-Jul-2021

$1.9 B

Moderna Revenue Q1, 2021
Moderna Gross profit (Q1, 2021)1.7 B
Moderna Gross profit margin (Q1, 2021), %90%
Moderna Net income (Q1, 2021)1.2 B
Moderna EBIT (Q1, 2021)1.3 B
Moderna Cash, 31-Mar-20215.4 B
Moderna EV123.7 B
Get notified regarding key financial metrics and revenue changes at ModernaLearn more
Banner background

Moderna Revenue Breakdown

Embed Graph

Moderna revenue breakdown by business segment: 14.0% from Grant revenue, 14.6% from Collaboration revenue from affiliate and 71.4% from Collaboration revenue

Moderna Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

108.4m205.8m135.1m60.2m803.4m

Revenue growth, %

90%

Cost of goods sold

7.9m

Gross profit

795.5m

Gross profit Margin, %

99%

R&D expense

274.7m410.5m454.1m496.3m1.4b

General and administrative expense

57.5m64.7m94.3m109.6m188.3m

Operating expense total

332.2m475.2m548.3m605.9m1.6b

EBIT

(223.8m)(269.4m)(413.3m)(545.7m)(763.1m)

EBIT margin, %

(206%)(131%)(306%)(906%)(95%)

Interest expense

Interest income

11.3m15.2m27.0m38.5m24.7m

Pre tax profit

(215.2m)(256.0m)(384.4m)(514.7m)(744.5m)

Income tax expense

1.0m(80.0k)326.0k(695.0k)2.6m

Net Income

(216.2m)(255.9m)(401.9m)(514.0m)(747.1m)

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

16.0m13.1m17.0m8.4m28.4m145.7m1.9b

Cost of goods sold

193.0m

Gross profit

1.7b

Gross profit Margin, %

90%

R&D expense

130.6m128.5m119.7m115.1m401.0m

General and administrative expense

27.3m28.5m28.2m24.1m77.0m

Operating expense total

157.9m157.0m147.9m139.3m478.0m

EBIT

(141.8m)(143.9m)(130.9m)(130.9m)1.3b

EBIT margin, %

(885%)(1100%)(768%)(1560%)65%

Interest income

11.0m10.3m9.3m7.9m4.0m

Pre tax profit

(132.7m)(135.4m)(123.4m)(124.2m)1.3b

Income tax expense

(24.0k)(324.0k)(178.0k)66.0k39.0m

Net Income

(132.7m)(135.1m)(123.2m)(124.2m)1.2b

Moderna Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

50.1m134.9m658.4m235.9m2.6b

Accounts Receivable

13.4m11.9m11.7m5.0m1.4b

Prepaid Expenses

15.5m12.8m28.4m19.4m252.2m

Inventories

46.5m

Current Assets

1.1b783.2m1.6b1.1b6.3b

PP&E

81.2m139.0m212.0m

Total Assets

1.4b1.1b2.0b1.6b7.3b

Accounts Payable

28.2m20.7m31.2m7.1m18.4m

Current Liabilities

162.8m191.5m222.8m143.1m4.4b

Long-term debt

4.7m77.6m132.4m207.3m

Total Debt

4.7m77.6m132.4m207.3m

Total Liabilities

575.3m459.2m431.9m414.6m4.8b

Common Stock

14.0k14.0k33.0k34.0k40.0k

Preferred Stock

1.2b1.2b

Additional Paid-in Capital

31.3m71.7m2.5b2.7b4.8b

Retained Earnings

(365.7m)(621.9m)(1.0b)(1.5b)(2.2b)

Total Equity

(334.8m)(551.4m)1.5b1.2b2.6b

Debt to Equity Ratio

0 x-0.1 x

Debt to Assets Ratio

0 x0.1 x

Financial Leverage

-4.2 x-2 x1.3 x1.4 x2.9 x

Quarterly

USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

167.1m502.9m151.6m173.7m391.7m1.8b1.5b5.4b

Accounts Receivable

9.8m5.6m3.5m2.8m5.6m33.4m190.5m3.2b

Prepaid Expenses

33.4m25.3m23.9m45.3m109.4m264.0m

Inventories

494.0m

Current Assets

1.1b1.1b1.1b1.1b1.2b2.8b3.6b11.7b

PP&E

206.5m213.5m208.5m203.7m

Total Assets

1.5b1.8b1.7b1.6b2.1b3.5b4.7b12.7b

Accounts Payable

23.4m38.5m29.6m11.7m11.0m18.8m20.5m8.0m

Current Liabilities

186.4m159.2m162.0m147.8m134.6m161.6m1.5b8.4b

Long-term debt

9.8m147.8m167.8m207.6m234.0m

Total Debt

9.8m147.8m167.8m207.6m234.0m

Total Liabilities

412.7m360.2m346.7m339.1m426.7m539.1m1.9b8.9b

Common Stock

14.0k33.0k37.0k39.0k40.0k

Preferred Stock

1.8b

Additional Paid-in Capital

109.0m2.6b2.6b2.6b3.3b4.7b4.7b4.9b

Retained Earnings

(865.2m)(1.1b)(1.2b)(1.4b)(1.6b)(1.7b)(2.0b)(1.0b)

Total Equity

(757.1m)1.4b1.3b1.3b1.6b2.9b2.8b3.8b

Financial Leverage

-2 x1.2 x1.3 x1.3 x1.3 x1.2 x1.7 x3.3 x

Moderna Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(216.2m)(255.9m)(514.0m)(747.1m)

Depreciation and Amortization

17.6m21.6m24.9m31.0m

Accounts Receivable

(8.6m)1.5m195.0k6.7m(1.4b)

Inventories

(46.5m)

Accounts Payable

6.0m(12.8m)15.0m(24.0m)11.9m

Cash From Operating Activities

66.7m(331.5m)(330.9m)(459.0m)2.0b

Purchases of PP&E

(33.1m)(58.4m)(105.8m)(31.6m)(67.4m)

Cash From Investing Activities

(648.6m)416.1m(372.5m)(14.9m)(1.7b)

Cash From Financing Activities

472.9m168.0k1.2b51.1m2.0b

Net Change in Cash

(109.0m)84.8m523.5m(422.8m)2.4b

Interest Paid

3.0m8.5m

Income Taxes Paid

905.0k398.0k294.0k416.0k572.0k

Quarterly

USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(243.3m)(218.0m)(132.7m)(267.7m)(390.9m)(124.2m)(240.9m)(474.6m)1.2b

Depreciation and Amortization

58.4m43.6m7.3m14.8m22.1m15.0m15.0m

Accounts Receivable

2.0m(712.0k)6.0m8.2m8.9m(585.0k)(28.0m)(185.1m)(1.8b)

Inventories

(448.0m)

Accounts Payable

718.0k(9.9m)1.7m(1.5m)(19.2m)2.3m11.5m13.6m(15.0m)

Cash From Operating Activities

(239.8m)(228.6m)(143.9m)(256.1m)(363.2m)(106.2m)(130.1m)762.7m3.0b

Purchases of PP&E

(92.1m)(46.4m)(7.6m)(18.2m)(24.9m)(6.2m)(24.9m)(44.1m)(35.0m)

Cash From Investing Activities

(378.9m)303.3m(11.8m)(258.7m)(145.3m)(316.0m)(303.5m)(1.5b)(180.0m)

Cash From Financing Activities

650.9m(1.4m)(48.0k)7.8m23.5m578.1m2.0b2.0b26.0m

Net Change in Cash

32.2m73.4m(155.7m)155.8m1.5b1.3b2.8b

Income Taxes Paid

240.0k398.0k

Moderna Ratios

USDFY, 2016

Revenue/Employee

302.9k

Financial Leverage

-4.2 x

Moderna Operating Metrics

Moderna's Clinical Programs was reported to be 10 in Q3, 2018.
Y, 2015May, 2017Q3, 2018

Clinical Programs

10

Drugs in Development

92

Patent Applications

250

Patents Issued

100

Patents and Patent Applications

1.5 k

Projects in Pipeline

21

Moderna Employee Rating

4.1153 votes
Culture & Values
4
Work/Life Balance
3.3
Senior Management
3.4
Salary & Benefits
4.3
Career Opportunities
3.9
Source